KYMR logo

Kymera Therapeutics, Inc. Common Stock

KYMR

KYMR: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

more

Show KYMR Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of KYMR by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by KYMR's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Irak degraders and uses thereof Aug. 15, 2023
  • Patent Title: Irak degraders and uses thereof Jul. 25, 2023
  • Patent Title: Crystalline forms of irak degraders Jun. 27, 2023
  • Patent Title: Smarca degraders and uses thereof Jun. 20, 2023
  • Patent Title: Protein degraders and uses thereof Apr. 11, 2023
  • Patent Title: Irak degraders and uses thereof Feb. 28, 2023
  • Patent Title: Crbn ligands and uses thereof Nov. 29, 2022
  • Patent Title: Stat degraders and uses thereof Nov. 01, 2022
  • Patent Title: Protein degraders and uses thereof Nov. 01, 2022
  • Patent Title: Crbn ligands and uses thereof Jun. 14, 2022
  • Patent Title: Irak degraders and uses thereof Jun. 07, 2022
  • Patent Title: Irak degraders and uses thereof May. 03, 2022
  • Patent Title: Tricyclic crbn ligands and uses thereof Apr. 05, 2022
  • Patent Title: Irak degraders and uses thereof Sep. 14, 2021
  • Patent Title: Irak degraders and uses thereof Dec. 29, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of KYMR in WallStreetBets Daily Discussion

KYMR News

Recent insights relating to KYMR

CNBC Recommendations

Recent picks made for KYMR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in KYMR

Corporate Flights

Flights by private jets registered to KYMR